LHRH agonists are a type of gonadotropin-releasing hormone agonist that can be used to treat a variety of conditions, including precocious puberty, endometriosis, prostate cancer, and breast cancer.
This document is a set of teaching slides (lectures) presented by pharmacists Chen Ye and Lu Caiping on November 9, 2017. It provides a comprehensive overview of Luteinizing Hormone-Releasing Hormone (LHRH) agonists, detailing their physiological mechanisms, clinical indications, and pharmacokinetic profiles. This manual is written in Chinese.
They are used for precocious puberty, prostate cancer, breast cancer, uterine fibroids, and endometriosis.
They should be administered via subcutaneous injection once every 4 weeks.
The recommended dosage is 3.6mg administered subcutaneously in the anterior abdominal wall every 28 days.